| 2017-11-20 18:08:51|
BIVV, RHHBY… 18:08 11/20 11/20/17
Deutsche cuts Bioverativ target to $53 after positive Roche data
Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.
See Street Research during your Free Trial